NO20051347L - eNOS-mutanter som er nyttige til genterapi. - Google Patents

eNOS-mutanter som er nyttige til genterapi.

Info

Publication number
NO20051347L
NO20051347L NO20051347A NO20051347A NO20051347L NO 20051347 L NO20051347 L NO 20051347L NO 20051347 A NO20051347 A NO 20051347A NO 20051347 A NO20051347 A NO 20051347A NO 20051347 L NO20051347 L NO 20051347L
Authority
NO
Norway
Prior art keywords
enos
polypeptide mutants
polypeptide
provides
amino acid
Prior art date
Application number
NO20051347A
Other languages
English (en)
Norwegian (no)
Inventor
Katalin Kauser
John Parkinson
Eric Blasko
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20051347L publication Critical patent/NO20051347L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C12N9/0075—Nitric-oxide synthase (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
NO20051347A 2002-08-16 2005-03-15 eNOS-mutanter som er nyttige til genterapi. NO20051347L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40363802P 2002-08-16 2002-08-16
PCT/US2003/025745 WO2004016764A2 (en) 2002-08-16 2003-08-15 eNOS MUTANTS USEFUL FOR GENE THERAPY

Publications (1)

Publication Number Publication Date
NO20051347L true NO20051347L (no) 2005-04-28

Family

ID=31888260

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051347A NO20051347L (no) 2002-08-16 2005-03-15 eNOS-mutanter som er nyttige til genterapi.

Country Status (15)

Country Link
US (1) US20040096881A1 (de)
EP (1) EP1553973A4 (de)
JP (1) JP2005535345A (de)
KR (1) KR20050042788A (de)
CN (1) CN1691958A (de)
AU (1) AU2003265461A1 (de)
BR (1) BR0313511A (de)
CA (1) CA2494847A1 (de)
IL (1) IL166511A0 (de)
MX (1) MXPA05001906A (de)
NO (1) NO20051347L (de)
PL (1) PL375219A1 (de)
RU (1) RU2005107410A (de)
WO (1) WO2004016764A2 (de)
ZA (1) ZA200502183B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050074448A1 (en) * 2003-03-24 2005-04-07 The Curator Sof The University Of Missouri Method of treatment of endothelial dysfunction and engineered proteins for same
PL1708690T3 (pl) 2003-11-17 2017-01-31 Biomarin Pharmaceutical Inc. Leczenie fenyloketonurii za pomocą BH4
US7964413B2 (en) 2005-03-10 2011-06-21 Gen-Probe Incorporated Method for continuous mode processing of multiple reaction receptacles in a real-time amplification assay
JP5068748B2 (ja) * 2005-06-22 2012-11-07 ジェン−プロウブ インコーポレイテッド ポリヌクレオチドを定量するための方法およびアルゴリズム
US10550178B2 (en) * 2010-03-18 2020-02-04 Srikanth Vedamoorthy Antibodies for detecting redox modulated proteins
WO2013049531A2 (en) * 2011-09-29 2013-04-04 University Of South Florida Multilayer magnetic micelle compositions and methods for their use
US9216178B2 (en) 2011-11-02 2015-12-22 Biomarin Pharmaceutical Inc. Dry blend formulation of tetrahydrobiopterin
US9782494B2 (en) 2012-02-23 2017-10-10 University Of South Florida Methods of using multilayer magnetic micelle compositions
WO2013154771A1 (en) * 2012-04-12 2013-10-17 Georgia Regents University Redox-resistant nitric oxide synthase
CN106415562B (zh) * 2014-06-25 2019-12-10 国立研究开发法人科学技术振兴机构 膜蛋白质的热稳定化突变体预测装置、热稳定化突变体预测方法、以及程序
CN107802826B (zh) * 2017-10-26 2020-02-18 首都医科大学宣武医院 eNOS突变体在促进血管生成中的应用
JP7636812B2 (ja) * 2019-07-29 2025-02-27 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティ オブ イリノイ 創傷治癒を促進するための組成物および方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA01010459A (es) * 1999-04-16 2003-08-20 Univ Yale Mutaciones de sintasa de oxido nitrico endotelial, utiles para terapia con genes y su depuracion terapeutica.
US6620616B1 (en) * 2000-09-13 2003-09-16 The Cleveland Clinic Foundation Nucleic acids encoding nitric oxide synthase variants

Also Published As

Publication number Publication date
AU2003265461A1 (en) 2004-03-03
CN1691958A (zh) 2005-11-02
CA2494847A1 (en) 2004-02-26
MXPA05001906A (es) 2005-04-28
ZA200502183B (en) 2006-09-27
WO2004016764A2 (en) 2004-02-26
EP1553973A2 (de) 2005-07-20
PL375219A1 (en) 2005-11-28
RU2005107410A (ru) 2006-01-20
WO2004016764A3 (en) 2005-05-19
KR20050042788A (ko) 2005-05-10
IL166511A0 (en) 2006-01-15
BR0313511A (pt) 2006-06-13
US20040096881A1 (en) 2004-05-20
EP1553973A4 (de) 2006-03-01
JP2005535345A (ja) 2005-11-24

Similar Documents

Publication Publication Date Title
Haney et al. Structural basis for thermostability and identification of potential active site residues for adenylate kinases from the archaeal genus Methanococcus
NO20051347L (no) eNOS-mutanter som er nyttige til genterapi.
Zivanovic et al. Genome analysis and genome-wide proteomics of Thermococcus gammatolerans, the most radioresistant organism known amongst the Archaea
Pointon et al. A highly unusual thioester bond in a pilus adhesin is required for efficient host cell interaction
Labahn et al. Structural basis for the excision repair of alkylation-damaged DNA
Kouzuma et al. Reconstitution of archaeal ribonuclease P from RNA and four protein components
Trincao et al. Structure of the catalytic core of S. cerevisiae DNA polymerase η: implications for translesion DNA synthesis
Lowe et al. Steady-state and pre-steady-state kinetic analysis of dNTP insertion opposite 8-oxo-7, 8-dihydroguanine by Escherichia coli polymerases I exo-and II exo
NO20092331L (no) LINGO-bindingsmolekyler og farmasoytisk anvendelse derav
Verma et al. Evaluation of gidB alterations responsible for streptomycin resistance in Mycobacterium tuberculosis
Landry Structure and energetics of an allele-specific genetic interaction between dnaJ and dnaK: correlation of nuclear magnetic resonance chemical shift perturbations in the J-domain of Hsp40/DnaJ with binding affinity for the ATPase domain of Hsp70/DnaK
NO20073808L (no) BCMA polypeptider og anvendelser derav
Vishwanath et al. Ribosomal protein-sequence block structure suggests complex prokaryotic evolution with implications for the origin of eukaryotes
Sergiev et al. The conserved A-site finger of the 23 S rRNA: just one of the intersubunit bridges or a part of the allosteric communication pathway?
Gvritishvili et al. Cooperativity of complex salt bridges
Paiardini et al. Threonine aldolase and alanine racemase: novel examples of convergent evolution in the superfamily of vitamin B6-dependent enzymes
Purta et al. Sequence–structure–function relationships of a tRNA (m7G46) methyltransferase studied by homology modeling and site‐directed mutagenesis
Sulpizi et al. The rational of catalytic activity of herpes simplex virus thymidine kinase: A combined biochemical and quantum chemical study
Lancelin et al. NMR structures of thioredoxin m from the green alga Chlamydomonas reinhardtii
Matsumoto et al. RNA recognition mechanism of eukaryote tRNA (m7G46) methyltransferase (Trm8–Trm82 complex)
Evans et al. NMR structure of the N-terminal domain of Saccharomyces cerevisiae RNase HI reveals a fold with a strong resemblance to the N-terminal domain of ribosomal protein L9
Fahie et al. Side chain specificity of ADP‐ribosylation by a sirtuin
AU4302000A (en) Genome sequence and polypeptides of pyrococcus (abissy), fragment and uses thereof
Geršak et al. Patellae as a Source of DNA in Forensic and Archaeological Analysis
Brandt et al. Stoichiometry and deletion analyses of subunits in the heterotrimeric F‐ATP synthase c ring from the acetogenic bacterium Acetobacterium woodii

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application